SFDA To Issue Regulation On Technology Transfer Registrations
This article was originally published in PharmAsia News
Executive Summary
China's State FDA has finalized its policy on technology transfer registration for drugs, which it will issue this month. The regulation will encourage adoption and implementation of mature or advanced production technology, while reducing the number of approvals for new generics. In addition, approval and supervision of transferred drugs will be tightened and will forbid transfer application of high-risk drugs, suspend transfer of drugs with newly detected safety risks and reject transfer of drugs with risks found during technology reviews. (Click here for more - Chinese Language)
You may also be interested in...
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.